PRP for Glenohumeral Osteoarthritis
Key facts
- Who runs it
- Hospital for Special Surgery, New York
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 135 people, planned
- Started
- 2 May 2023
- Expected to end
- 1 Jun 2029
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Low-dose PRP
- High-dose PRP
- Saline
- Record updated
- 9 October 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- 18-100 years old
- Average NRS pain greater than or equal to 5/10 as a direct result of glenohumeral osteoarthritis (any severity: mild, moderate, or severe) and/or chondral lesion or loss
- At least 3 months of pain after onset of symptoms that has failed conservative treatments, including physical therapy
- MRI of the affected joint
- Transient relief of symptoms after a diagnostic intra-articular injection into the joint
- Email address or network access
Who cannot take part
- Inability to hold non-steroidal anti-inflammatory drugs for 2 weeks prior and 1 month after the injection
- Steroid injection within 3 months of the initial injection
- Concurrent "uncontrolled" cervical disorders
- History of Plavix use
- Known uncontrolled systemic illness (uncontrolled diabetes, HIV, vasculitis, autoimmune/autoinflammatory disease)
- Prior platelet-rich plasma injection
- Hyaluronic acid within 6 months of the initial injection
- Involved in workers' compensation or active litigation involving the affected joint
- Presence of acute fractures or gross mechanical deformities
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in United States
- Hospital for Special SurgeryNew York, United StatesContact: Jonathan Kirschner, MDTaking people
About the trial
What the trial wants to find out
The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.
The 3 groups in the trial
- Low-dose PRPTreatment being tested
Patients will receive a single injection of 6 ml low-dose platelet-rich plasma (PRP) into the glenohumeral joint. Low-dose is defined as a platelet yield of 3X (i.e., 3-fold increase in platelets in PRP compared to whole blood).
- High-dose PRPTreatment being tested
Patients will receive a single injection of 6 ml high-dose platelet-rich plasma (PRP) into the glenohumeral joint. High-dose is defined as a platelet yield of 12X (i.e., 12-fold increase in platelets in PRP compared to whole blood).
- Saline controlPlacebo, for comparison
Patients will receive a single injection of 6 ml saline into the glenohumeral joint.
Treatment: Saline
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Outcomes Following Single Injections of Low-dose Platelet-rich Plasma (PRP), High-dose PRP, or Saline in Patients With Glenohumeral OA: a Randomized Controlled Trial
- Fit questions
- Built from NCT05675527, who can take part
- Record updated
- 9 October 2026